Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

Biophysical and in Vivo Studies Identify a New Natural-Based Polyphenol, Counteracting Aβ Oligomerization in Vitro and Aβ Oligomer-Mediated Memory Impairment and Neuroinflammation in an Acute Mouse Model of Alzheimer's Disease.

Tomaselli S, La Vitola P, Pagano K, Brandi E, Santamaria G, Galante D, D'Arrigo C, Moni L, Lambruschini C, Banfi L, Lucchetti J, Fracasso C, Molinari H, Forloni G, Balducci C, Ragona L.

ACS Chem Neurosci. 2019 Nov 20;10(11):4462-4475. doi: 10.1021/acschemneuro.9b00241. Epub 2019 Oct 28.

PMID:
31603646
2.

AKT-dependent phosphorylation of the adenosine deaminases ADAR-1 and -2 inhibits deaminase activity.

Bavelloni A, Focaccia E, Piazzi M, Raffini M, Cesarini V, Tomaselli S, Orsini A, Ratti S, Faenza I, Cocco L, Gallo A, Blalock WL.

FASEB J. 2019 Aug;33(8):9044-9061. doi: 10.1096/fj.201800490RR. Epub 2019 May 16.

PMID:
31095429
3.

5-hydroxymethylcytosine but not MTAP methylation status can stratify malignant pleural mesothelioma based on the lineage of origin.

Bosio M, Salvaterra E, Datturi F, Morbini P, Zorzetto M, Inghilleri S, Tomaselli S, Mangiarotti P, Meloni F, Cerveri I, Stella GM.

Multidiscip Respir Med. 2018 Aug 2;13:27. doi: 10.1186/s40248-018-0137-4. eCollection 2018.

4.

Effects of Prion Protein on Aβ42 and Pyroglutamate-Modified AβpΕ3-42 Oligomerization and Toxicity.

Pagano K, Galante D, D'Arrigo C, Corsaro A, Nizzari M, Florio T, Molinari H, Tomaselli S, Ragona L.

Mol Neurobiol. 2019 Mar;56(3):1957-1971. doi: 10.1007/s12035-018-1202-x. Epub 2018 Jul 6.

PMID:
29981054
5.

Pharmacodynamics of inhaled amikacin (BAY 41-6551) studied in an in vitro pharmacokinetic model of infection.

Bowker KE, Noel AR, Tomaselli S, Attwood M, MacGowan AP.

J Antimicrob Chemother. 2018 May 1;73(5):1305-1313. doi: 10.1093/jac/dky002.

PMID:
29562340
6.

ADAR2/miR-589-3p axis controls glioblastoma cell migration/invasion.

Cesarini V, Silvestris DA, Tassinari V, Tomaselli S, Alon S, Eisenberg E, Locatelli F, Gallo A.

Nucleic Acids Res. 2018 Feb 28;46(4):2045-2059. doi: 10.1093/nar/gkx1257.

7.

Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe.

Marshall AD, Cunningham EB, Nielsen S, Aghemo A, Alho H, Backmund M, Bruggmann P, Dalgard O, Seguin-Devaux C, Flisiak R, Foster GR, Gheorghe L, Goldberg D, Goulis I, Hickman M, Hoffmann P, Jancorienė L, Jarcuska P, Kåberg M, Kostrikis LG, Makara M, Maimets M, Marinho RT, Matičič M, Norris S, Ólafsson S, Øvrehus A, Pawlotsky JM, Pocock J, Robaeys G, Roncero C, Simonova M, Sperl J, Tait M, Tolmane I, Tomaselli S, van der Valk M, Vince A, Dore GJ, Lazarus JV, Grebely J; International Network on Hepatitis in Substance Users (INHSU).

Lancet Gastroenterol Hepatol. 2018 Feb;3(2):125-133. doi: 10.1016/S2468-1253(17)30284-4. Epub 2017 Oct 3.

PMID:
28986139
8.

Pharmacodynamics of minocycline against Acinetobacter baumannii studied in a pharmacokinetic model of infection.

Alfouzan WA, Noel AR, Bowker KE, Attwood MLG, Tomaselli SG, MacGowan AP.

Int J Antimicrob Agents. 2017 Dec;50(6):715-717. doi: 10.1016/j.ijantimicag.2017.06.026. Epub 2017 Jul 10.

PMID:
28705678
9.

Evidence of Molecular Interactions of Aβ1-42 with N-Terminal Truncated Beta Amyloids by NMR.

Tomaselli S, Pagano K, D'Arrigo C, Molinari H, Ragona L.

ACS Chem Neurosci. 2017 Apr 19;8(4):759-765. doi: 10.1021/acschemneuro.6b00456. Epub 2017 Feb 6.

PMID:
28135060
10.

The pharmacodynamics of avibactam in combination with ceftaroline or ceftazidime against β-lactamase-producing Enterobacteriaceae studied in an in vitro model of infection.

MacGowan A, Tomaselli S, Noel A, Bowker K.

J Antimicrob Chemother. 2017 Mar 1;72(3):762-769. doi: 10.1093/jac/dkw480.

PMID:
28039276
11.

Electrospun Lipid Binding Proteins Composite Nanofibers with Antibacterial Properties.

Tomaselli S, Ramirez DO, Carletto RA, Varesano A, Vineis C, Zanzoni S, Molinari H, Ragona L.

Macromol Biosci. 2017 Apr;17(4). doi: 10.1002/mabi.201600300. Epub 2016 Nov 2.

PMID:
27805768
12.

Differences in the pharmacodynamics of ceftaroline against different species of Enterobacteriaceae studied in an in vitro pharmacokinetic model of infection.

Bowker KE, Noel AR, Tomaselli S, MacGowan AP.

J Antimicrob Chemother. 2016 May;71(5):1270-8. doi: 10.1093/jac/dkv480. Epub 2016 Feb 3.

PMID:
26846209
13.

Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of Infection.

MacGowan AP, Noel AR, Tomaselli SG, Nicholls D, Bowker KE.

Antimicrob Agents Chemother. 2015 Nov 9;60(1):515-21. doi: 10.1128/AAC.00727-15. Print 2016 Jan.

14.

Lipid binding protein response to a bile acid library: a combined NMR and statistical approach.

Tomaselli S, Pagano K, Boulton S, Zanzoni S, Melacini G, Molinari H, Ragona L.

FEBS J. 2015 Nov;282(21):4094-113. doi: 10.1111/febs.13405. Epub 2015 Sep 11.

15.

The study of transient protein-nanoparticle interactions by solution NMR spectroscopy.

Assfalg M, Ragona L, Pagano K, D'Onofrio M, Zanzoni S, Tomaselli S, Molinari H.

Biochim Biophys Acta Proteins Proteom. 2016 Jan;1864(1):102-14. doi: 10.1016/j.bbapap.2015.04.024. Epub 2015 Apr 30. Review.

PMID:
25936778
16.

Modulation of microRNA editing, expression and processing by ADAR2 deaminase in glioblastoma.

Tomaselli S, Galeano F, Alon S, Raho S, Galardi S, Polito VA, Presutti C, Vincenti S, Eisenberg E, Locatelli F, Gallo A.

Genome Biol. 2015 Jan 13;16:5. doi: 10.1186/s13059-014-0575-z.

17.

ADARs and the Balance Game between Virus Infection and Innate Immune Cell Response.

Tomaselli S, Galeano F, Locatelli F, Gallo A.

Curr Issues Mol Biol. 2015;17:37-51. Epub 2014 Dec 11. Review.

18.

The RNA editing enzymes ADARs: mechanism of action and human disease.

Tomaselli S, Locatelli F, Gallo A.

Cell Tissue Res. 2014 Jun;356(3):527-32. doi: 10.1007/s00441-014-1863-3. Epub 2014 Apr 26. Review.

PMID:
24770896
19.

The role of dynamics in modulating ligand exchange in intracellular lipid binding proteins.

Ragona L, Pagano K, Tomaselli S, Favretto F, Ceccon A, Zanzoni S, D'Onofrio M, Assfalg M, Molinari H.

Biochim Biophys Acta. 2014 Jul;1844(7):1268-78. doi: 10.1016/j.bbapap.2014.04.011. Epub 2014 Apr 21. Review.

PMID:
24768771
20.

Oligophrenin-1 (OPHN1), a gene involved in X-linked intellectual disability, undergoes RNA editing and alternative splicing during human brain development.

Barresi S, Tomaselli S, Athanasiadis A, Galeano F, Locatelli F, Bertini E, Zanni G, Gallo A.

PLoS One. 2014 Mar 17;9(3):e91351. doi: 10.1371/journal.pone.0091351. eCollection 2014.

21.

ADAR enzyme and miRNA story: a nucleotide that can make the difference.

Tomaselli S, Bonamassa B, Alisi A, Nobili V, Locatelli F, Gallo A.

Int J Mol Sci. 2013 Nov 19;14(11):22796-816. doi: 10.3390/ijms141122796. Review.

22.

Encapsulation of a rhodamine dye within a bile acid binding protein: toward water processable functional bio host-guest materials.

Tomaselli S, Giovanella U, Pagano K, Leone G, Zanzoni S, Assfalg M, Meinardi F, Molinari H, Botta C, Ragona L.

Biomacromolecules. 2013 Oct 14;14(10):3549-56. doi: 10.1021/bm400904s. Epub 2013 Sep 30.

PMID:
24032431
23.

ADAR2 editing activity in newly diagnosed versus relapsed pediatric high-grade astrocytomas.

Tomaselli S, Galeano F, Massimi L, Di Rocco C, Lauriola L, Mastronuzzi A, Locatelli F, Gallo A.

BMC Cancer. 2013 May 22;13:255. doi: 10.1186/1471-2407-13-255.

24.

Pharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection.

MacGowan AP, Noel AR, Tomaselli S, Bowker KE.

Antimicrob Agents Chemother. 2013 Jun;57(6):2451-6. doi: 10.1128/AAC.01386-12. Epub 2013 Mar 4.

25.

Comparative antibacterial effects of moxifloxacin and levofloxacin on Streptococcus pneumoniae strains with defined mechanisms of resistance: impact of bacterial inoculum.

Bowker KE, Garvey MI, Noel AR, Tomaselli SG, Macgowan AP.

J Antimicrob Chemother. 2013 May;68(5):1130-8. doi: 10.1093/jac/dks537. Epub 2013 Jan 29.

PMID:
23361641
26.

Bile acid binding protein: a versatile host of small hydrophobic ligands for applications in the fields of MRI contrast agents and bio-nanomaterials.

Pagano K, Tomaselli S, Zanzoni S, Assfalg M, Molinari H, Ragona L.

Comput Struct Biotechnol J. 2013 Dec 8;6:e201303021. doi: 10.5936/csbj.201303021. eCollection 2013. Review.

27.

Circulating miRNA profiling to identify biomarkers of dysmetabolism.

Tomaselli S, Panera N, Gallo A, Alisi A.

Biomark Med. 2012 Dec;6(6):729-42. doi: 10.2217/bmm.12.91. Review.

PMID:
23227838
28.

A novel computational strategy to identify A-to-I RNA editing sites by RNA-Seq data: de novo detection in human spinal cord tissue.

Picardi E, Gallo A, Galeano F, Tomaselli S, Pesole G.

PLoS One. 2012;7(9):e44184. doi: 10.1371/journal.pone.0044184. Epub 2012 Sep 5.

29.

Pharmacodynamics of the antibacterial effect of and emergence of resistance to doripenem in Pseudomonas aeruginosa and Acinetobacter baumannii in an in vitro pharmacokinetic model.

Bowker KE, Noel AR, Tomaselli SG, Elliott H, Macgowan AP.

Antimicrob Agents Chemother. 2012 Oct;56(10):5009-15. doi: 10.1128/AAC.06111-11. Epub 2012 Jun 19.

30.

Direct and allosteric inhibition of the FGF2/HSPGs/FGFR1 ternary complex formation by an antiangiogenic, thrombospondin-1-mimic small molecule.

Pagano K, Torella R, Foglieni C, Bugatti A, Tomaselli S, Zetta L, Presta M, Rusnati M, Taraboletti G, Colombo G, Ragona L.

PLoS One. 2012;7(5):e36990. doi: 10.1371/journal.pone.0036990. Epub 2012 May 14.

31.

ADAR2-editing activity inhibits glioblastoma growth through the modulation of the CDC14B/Skp2/p21/p27 axis.

Galeano F, Rossetti C, Tomaselli S, Cifaldi L, Lezzerini M, Pezzullo M, Boldrini R, Massimi L, Di Rocco CM, Locatelli F, Gallo A.

Oncogene. 2013 Feb 21;32(8):998-1009. doi: 10.1038/onc.2012.125. Epub 2012 Apr 23.

32.

Structural dynamics of bacterial translation initiation factor IF2.

Wienk H, Tishchenko E, Belardinelli R, Tomaselli S, Dongre R, Spurio R, Folkers GE, Gualerzi CO, Boelens R.

J Biol Chem. 2012 Mar 30;287(14):10922-32. doi: 10.1074/jbc.M111.333393. Epub 2012 Feb 3.

33.

A disulfide bridge allows for site-selective binding in liver bile acid binding protein thereby stabilising the orientation of key amino acid side chains.

Tomaselli S, Assfalg M, Pagano K, Cogliati C, Zanzoni S, Molinari H, Ragona L.

Chemistry. 2012 Mar 5;18(10):2857-66. doi: 10.1002/chem.201102203. Epub 2012 Feb 1. Erratum in: Chemistry. 2013 Mar 25;19(13):4092.

PMID:
22298334
34.

A-to-I RNA editing: the "ADAR" side of human cancer.

Galeano F, Tomaselli S, Locatelli F, Gallo A.

Semin Cell Dev Biol. 2012 May;23(3):244-50. doi: 10.1016/j.semcdb.2011.09.003. Epub 2011 Sep 13. Review.

PMID:
21930228
35.

Hepatitis C virus therapeutics: editing enzymes promising therapeutic targets?

Alisi A, Tomaselli S, Balsano C, Gallo A.

Hepatology. 2011 Aug;54(2):742; author reply 742-3. doi: 10.1002/hep.24409. No abstract available.

PMID:
21563199
36.

Human RSPO1/R-spondin1 is expressed during early ovary development and augments β-catenin signaling.

Tomaselli S, Megiorni F, Lin L, Mazzilli MC, Gerrelli D, Majore S, Grammatico P, Achermann JC.

PLoS One. 2011 Jan 28;6(1):e16366. doi: 10.1371/journal.pone.0016366.

37.

ADAR2 editing enzyme is a novel human immunodeficiency virus-1 proviral factor.

Doria M, Tomaselli S, Neri F, Ciafrè SA, Farace MG, Michienzi A, Gallo A.

J Gen Virol. 2011 May;92(Pt 5):1228-32. doi: 10.1099/vir.0.028043-0. Epub 2011 Feb 2.

PMID:
21289159
38.

Pharmacodynamics of razupenem (PZ601) studied in an in vitro pharmacokinetic model of infection.

MacGowan AP, Noel A, Tomaselli S, Elliott H, Bowker K.

Antimicrob Agents Chemother. 2011 Apr;55(4):1436-42. doi: 10.1128/AAC.00936-10. Epub 2011 Jan 24.

39.

Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection.

MacGowan AP, Noel AR, Tomaselli S, Elliott HC, Bowker KE.

Antimicrob Agents Chemother. 2011 Feb;55(2):867-73. doi: 10.1128/AAC.00933-10. Epub 2010 Nov 15.

40.

Combined in silico and experimental approach for drug design: the binding mode of peptidic and non-peptidic inhibitors to hsp90 N-terminal domain.

Tomaselli S, Meli M, Plescia J, Zetta L, Altieri DC, Colombo G, Ragona L.

Chem Biol Drug Des. 2010 Nov;76(5):382-91. doi: 10.1111/j.1747-0285.2010.01015.x.

41.

Site-specific investigation of the steady-state kinetics and dynamics of the multistep binding of bile acid molecules to a lipid carrier protein.

Cogliati C, Ragona L, D'Onofrio M, Günther U, Whittaker S, Ludwig C, Tomaselli S, Assfalg M, Molinari H.

Chemistry. 2010 Oct 4;16(37):11300-10. doi: 10.1002/chem.201000498.

PMID:
20715194
42.

Non-peptidic thrombospondin-1 mimics as fibroblast growth factor-2 inhibitors: an integrated strategy for the development of new antiangiogenic compounds.

Colombo G, Margosio B, Ragona L, Neves M, Bonifacio S, Annis DS, Stravalaci M, Tomaselli S, Giavazzi R, Rusnati M, Presta M, Zetta L, Mosher DF, Ribatti D, Gobbi M, Taraboletti G.

J Biol Chem. 2010 Mar 19;285(12):8733-42. doi: 10.1074/jbc.M109.085605. Epub 2010 Jan 7.

43.

Disulfide bridge regulates ligand-binding site selectivity in liver bile acid-binding proteins.

Cogliati C, Tomaselli S, Assfalg M, Pedò M, Ferranti P, Zetta L, Molinari H, Ragona L.

FEBS J. 2009 Oct;276(20):6011-23. doi: 10.1111/j.1742-4658.2009.07309.x. Epub 2009 Sep 15.

44.

Fibroblast growth factor 2-antagonist activity of a long-pentraxin 3-derived anti-angiogenic pentapeptide.

Leali D, Bianchi R, Bugatti A, Nicoli S, Mitola S, Ragona L, Tomaselli S, Gallo G, Catello S, Rivieccio V, Zetta L, Presta M.

J Cell Mol Med. 2010 Aug;14(8):2109-21. doi: 10.1111/j.1582-4934.2009.00855.x. Epub 2010 Jul 20.

45.

New insights into the molecular interaction of the C-terminal sequence of CXCL4 with fibroblast growth factor-2.

Ragona L, Tomaselli S, Quemener C, Zetta L, Bikfalvi A.

Biochem Biophys Res Commun. 2009 Apr 24;382(1):26-9. doi: 10.1016/j.bbrc.2009.02.092. Epub 2009 Feb 24.

PMID:
19245795
46.

Solution structure of the C-terminal domain of multiprotein bridging factor 1 (MBF1) of Trichoderma reesei.

Salinas RK, Camilo CM, Tomaselli S, Valencia EY, Farah CS, El-Dorry H, Chambergo FS.

Proteins. 2009 May 1;75(2):518-23. doi: 10.1002/prot.22344. No abstract available.

PMID:
19137618
47.

Solution structure of the supramolecular adduct between a liver cytosolic bile acid binding protein and a bile acid-based gadolinium(III)-chelate, a potential hepatospecific magnetic resonance imaging contrast agent.

Tomaselli S, Zanzoni S, Ragona L, Gianolio E, Aime S, Assfalg M, Molinari H.

J Med Chem. 2008 Nov 13;51(21):6782-92. doi: 10.1021/jm800820b. Epub 2008 Oct 22.

PMID:
18939814
48.

Conformational and dynamics changes induced by bile acids binding to chicken liver bile acid binding protein.

Eberini I, Guerini Rocco A, Ientile AR, Baptista AM, Gianazza E, Tomaselli S, Molinari H, Ragona L.

Proteins. 2008 Jun;71(4):1889-98. doi: 10.1002/prot.21875.

PMID:
18175325
49.

Syndromic true hermaphroditism due to an R-spondin1 (RSPO1) homozygous mutation.

Tomaselli S, Megiorni F, De Bernardo C, Felici A, Marrocco G, Maggiulli G, Grammatico B, Remotti D, Saccucci P, Valentini F, Mazzilli MC, Majore S, Grammatico P.

Hum Mutat. 2008 Feb;29(2):220-6.

PMID:
18085567
50.

Supplemental Content

Loading ...
Support Center